Citigroup Cuts Teladoc Health (NYSE:TDOC) Price Target to $9.00

Teladoc Health (NYSE:TDOC) had its target price decreased by Citigroup from $10.00 to $9.00 in a research note issued to investors on Friday,Benzinga reports. Citigroup currently has a neutral rating on the health services provider’s stock.

TDOC has been the subject of a number of other reports. Zacks Research lowered shares of Teladoc Health from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 10th. Bank of America dropped their target price on Teladoc Health from $9.00 to $8.00 and set a “neutral” rating on the stock in a report on Tuesday, November 25th. BMO Capital Markets started coverage on Teladoc Health in a research report on Thursday, November 13th. They issued a “market perform” rating and a $8.00 target price for the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Teladoc Health in a research report on Monday, December 29th. Finally, Evercore ISI dropped their price objective on Teladoc Health from $9.00 to $8.00 and set an “in-line” rating on the stock in a research note on Thursday, October 30th. Five investment analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $9.50.

Teladoc Health Trading Down 2.0%

NYSE:TDOC opened at $7.46 on Friday. Teladoc Health has a 1 year low of $6.35 and a 1 year high of $15.21. The stock has a market cap of $1.32 billion, a price-to-earnings ratio of -5.82 and a beta of 2.04. The business has a fifty day moving average of $7.38 and a 200-day moving average of $7.81. The company has a debt-to-equity ratio of 0.71, a quick ratio of 2.60 and a current ratio of 2.70.

Teladoc Health (NYSE:TDOC) last issued its quarterly earnings data on Wednesday, October 29th. The health services provider reported ($0.21) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.05. The business had revenue of $626.44 million for the quarter, compared to analysts’ expectations of $625.66 million. Teladoc Health had a negative net margin of 8.84% and a negative return on equity of 10.59%. The company’s revenue was down 2.2% on a year-over-year basis. During the same period in the previous year, the business earned ($0.19) earnings per share. Teladoc Health has set its Q4 2025 guidance at -0.250–0.100 EPS. Equities analysts predict that Teladoc Health will post -1.16 earnings per share for the current year.

Insider Buying and Selling

In other news, insider Adam C. Vandervoort sold 5,720 shares of the stock in a transaction on Tuesday, December 2nd. The stock was sold at an average price of $7.49, for a total transaction of $42,842.80. Following the completion of the sale, the insider owned 80,732 shares in the company, valued at approximately $604,682.68. This represents a 6.62% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Charles Divita III sold 17,138 shares of Teladoc Health stock in a transaction on Thursday, December 11th. The stock was sold at an average price of $7.63, for a total value of $130,762.94. Following the completion of the transaction, the chief executive officer owned 201,036 shares in the company, valued at $1,533,904.68. The trade was a 7.86% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 33,288 shares of company stock worth $251,684 over the last quarter. 0.58% of the stock is currently owned by insiders.

Institutional Trading of Teladoc Health

Institutional investors and hedge funds have recently bought and sold shares of the stock. AFG Fiduciary Services Limited Partnership purchased a new stake in Teladoc Health during the fourth quarter valued at about $92,000. IFP Advisors Inc raised its holdings in shares of Teladoc Health by 412.1% during the third quarter. IFP Advisors Inc now owns 3,989 shares of the health services provider’s stock valued at $31,000 after acquiring an additional 3,210 shares during the period. CIBC Bancorp USA Inc. purchased a new stake in shares of Teladoc Health in the 3rd quarter valued at approximately $145,000. CANADA LIFE ASSURANCE Co lifted its position in shares of Teladoc Health by 8.0% in the 3rd quarter. CANADA LIFE ASSURANCE Co now owns 60,231 shares of the health services provider’s stock valued at $494,000 after acquiring an additional 4,458 shares in the last quarter. Finally, Verition Fund Management LLC boosted its stake in Teladoc Health by 152.0% in the 3rd quarter. Verition Fund Management LLC now owns 218,572 shares of the health services provider’s stock worth $1,690,000 after purchasing an additional 131,833 shares during the period. Institutional investors and hedge funds own 76.82% of the company’s stock.

About Teladoc Health

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.